Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811281 | 0.82 | GLA (0.49) | GLANPSR1ABCB1TRPA1MAOB | |
| SCHEMBL3093178 | 0.82 | GLA (0.58) | GLANPSR1ABCB1MDM2 | |
| SCHEMBL9193771 | 0.80 | GLA (0.69) | GLANPSR1TRPA1MDM2 | |
| SCHEMBL16460894 | 0.79 | GLA (0.67) | GLANPSR1TRPA1CA12CA9 | |
| SCHEMBL15647719 | 0.79 | GLA (0.67) | GLANPSR1TRPA1CA12CA9 | |
| SCHEMBL15570301 | 0.79 | GLA (0.67) | GLANPSR1MAOBPOLBMDM2 | |
| SCHEMBL7417047 | 0.78 | GLA (0.66) | GLANPSR1ELANEMDM2 | |
| SCHEMBL16374867 | 0.77 | GLA (0.73) | GLANPSR1POLB | |
| SCHEMBL15569868 | 0.76 | NPSR1 (1.00) | GLANPSR1 | |
| SCHEMBL15647578 | 0.75 | GLA (0.61) | GLANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265867-B1 | MALONIC ACID DERIVATES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS INHIBITOR OF FACTOR XA ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2005-12-28 | — | — | EP | disclosed |
| US-6794365-B2 | INHIBITORS OF THE BLOOD CLOTTING ENZYME FACTOR XA; TREATING THROMBOEMBOLIC DISEASES; TRIFLUOROACETIC ACID SALT OF 2-(4-CARBAMIMIDOYL-BENZYL)-N-((1-CARBAMOYL-4-GUANIDINO-BUTYLCARBAMOYL) -CYCLOHEXYL-METHYL)-N',N'-DIMETHYL-MALONAMIDE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-21 | — | — | US | disclosed |
| US-6759384-B1 | LOW MOLECULAR WEIGHT ANTICOAGULANTS WITHOUT SIDE EFFECTS; DERIVATIVES OF AT LEAST PROLINE, LEUCINE AND ARGININE SEQUENCE | AVENTIS PHARMACEUTICALS INC. | 2004-07-06 | — | — | US | disclosed |
| EP-0758341-B1 | FACTOR Xa INHIBITORS | AVENTIS PHARMA INC (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1384725-A2 | Factor Xa inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1265867-A1 | NOVEL MALONIC ACID DERIVATES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS INHIBITOR OF FACTOR XA ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-12-18 | — | — | EP | disclosed |
| US-6395737-B1 | ANTICOAGULANTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-28 | — | — | US | disclosed |
| US-20020022596-A1 | Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-02-21 | — | — | US | disclosed |
| EP-1140878-A1 | NOVEL MALONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ( INHIBITIO OF FACTOR XA ACTIVITY ) | Aventis Pharma Deutschland GmbH (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001062735-A1 | NOVEL MALONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS INHIBITOR OF FACTOR XA ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-30 | — | — | WO | disclosed |
| EP-1127884-A1 | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them | Aventis Pharma Deutschland GmbH (DE) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000040571-A1 | NOVEL MALONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM (INHIBITION OF FACTOR XA ACTIVITY) | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-07-13 | — | — | WO | disclosed |
| EP-1016663-A1 | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) | Aventis Pharma Deutschland GmbH (DE) | 2000-07-05 | — | — | EP | disclosed |
| US-5849510-A | Factor Xa inhibitors | SELECTIDE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022596-A1 | Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them | F12, ME1, F11 | GLA 318/4885NPSR1 3980/4885CYP2A6 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.